/
NVCR
$15.48+$0.05 (+0.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.8B
116M shares
52-week range
$9.82 – $18.92
62% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-206.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $248.1M | $351.3M | $494.4M | $535.0M | $537.8M | $509.3M | $605.2M | $655.4M |
| Cost of revenue | $80.0M | $88.6M | $106.5M | $114.9M | $114.9M | $128.3M | $137.2M | $166.9M |
| Gross profit | $168.0M | $262.7M | $387.9M | $420.2M | $423.0M | $381.1M | $468.0M | $488.5M |
| Gross margin | 67.7% | 74.8% | 78.5% | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| R&D | $50.6M | $79.0M | $132.0M | $201.3M | $206.1M | $223.1M | $209.6M | $224.5M |
| Operating income | −$33.7M | −$914.0K | $30.4M | −$44.3M | −$89.5M | −$232.9M | −$170.5M | −$153.8M |
| EBITDA | −$23.4M | $13.4M | $44.8M | −$38.4M | −$67.9M | −$177.5M | −$109.6M | −$119.0M |
| Net income | −$63.6M | −$7.2M | $19.8M | −$58.4M | −$92.5M | −$207.0M | −$168.6M | −$136.2M |
| Net margin | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| EPS (diluted) | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $704M | $-1.59 | $-1.85–$-1.33 | 6 |
| 2027 | $774M | $-1.19 | $-1.33–$-0.94 | 6 |
| 2028 | $916M | $-0.73 | $-1.02–$-0.49 | 4 |
| 2029 | $1.5B | $1.95 | $1.90–$2.02 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
NovoCure Limited Ordinary Shares
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
www.novocure.com- Employees
- 1,605
- IPO / List date
- Oct 2, 2015
- HQ
- ST. HELIER
Held by traders on TradeandTell
No one on the platform currently holds NVCR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NVCR as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NVCR yet.
